300 related articles for article (PubMed ID: 25835078)
1. Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model.
Parvinian A; Casadaban LC; Hauck ZZ; van Breemen RB; Gaba RC
Diagn Interv Radiol; 2015; 21(3):235-40. PubMed ID: 25835078
[TBL] [Abstract][Full Text] [Related]
2. Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect.
Kim GM; Kim MD; Kim do Y; Kim SH; Won JY; Park SI; Lee do Y; Shin W; Shin M
J Vasc Interv Radiol; 2016 Jul; 27(7):1086-92. PubMed ID: 27179404
[TBL] [Abstract][Full Text] [Related]
3. Transarterial embolization with sorafenib in animal livers: a pharmacokinetics study.
Chatziioannou AN; Siskos AP; Loxas D; Kavatzas N; Agrogiannis G; Fokas D; Malagari K; Kostomitsopoulos NG; Tsigkou O; Tamvakopoulos C
J Vasc Interv Radiol; 2013 Nov; 24(11):1657-63.e1. PubMed ID: 24060438
[TBL] [Abstract][Full Text] [Related]
4. Transarterial sorafenib chemoembolization: preliminary study of technical feasibility in a rabbit model.
Gaba RC; Yap FY; Martinez EM; Li Y; Guzman G; Parvinian A; van Breemen RB; Kumar N
J Vasc Interv Radiol; 2013 May; 24(5):744-50. PubMed ID: 23510657
[TBL] [Abstract][Full Text] [Related]
5. Hepatic arterial administration of sorafenib and iodized oil effectively attenuates tumor growth and intrahepatic metastasis in rabbit VX2 hepatocellular carcinoma model.
Zhang L; Liu FY; Fu JX; Duan F; Fan QS; Wang MQ
Int J Clin Exp Pathol; 2014; 7(11):7775-81. PubMed ID: 25550815
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Early Tumor Response to Conventional Transarterial Chemoembolization with Sorafenib and Doxorubicin in a VX2 Rabbit Tumor Model.
Elkhadragy L; Khabbaz RC; Muchiri RN; Totura WM; Samuelson JP; Whiteley HE; van Breemen RB; Lokken RP; Gaba RC
J Vasc Interv Radiol; 2022 Oct; 33(10):1213-1221.e5. PubMed ID: 35850455
[TBL] [Abstract][Full Text] [Related]
7. Modified transarterial chemoembolization with locoregional administration of sorafenib for treating hepatocellular carcinoma: feasibility, efficacy, and safety in the VX-2 rabbit liver tumor model.
Seidensticker M; Streit S; Nass N; Wybranski C; Jürgens J; Brauner J; Schulz N; Kalinski T; Seidensticker R; Garlipp B; Steffen I; Ricke J; Dudeck O
Diagn Interv Radiol; 2016; 22(4):378-84. PubMed ID: 27328720
[TBL] [Abstract][Full Text] [Related]
8. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.
Liu F; Meng Z; Shao G; Wang J; Wang Z; Yang J; Yip CS; He D
Mol Biol Rep; 2017 Feb; 44(1):149-158. PubMed ID: 27981445
[TBL] [Abstract][Full Text] [Related]
9. Intra-arterial interleukin-12 gene delivery combined with chemoembolization: anti-tumor effect in a rabbit hepatocellular carcinoma (HCC) model.
Xia X; Li X; Feng G; Zheng C; Liang H; Zhou G
Acta Radiol; 2013 Jul; 54(6):684-9. PubMed ID: 23507934
[TBL] [Abstract][Full Text] [Related]
10. Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting.
Kondo M; Morimoto M; Ishii T; Nozaki A; Fukuda H; Numata K; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Shibuya A; Okuse C; Suzuki M; Sakamaki K; Morita S; Maeda S; Tanaka K
J Dig Dis; 2015 Mar; 16(3):143-51. PubMed ID: 25495751
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Geschwind JF; Chapiro J
Clin Adv Hematol Oncol; 2016 Aug; 14(8):585-7. PubMed ID: 27487101
[No Abstract] [Full Text] [Related]
12. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
Fukudo M; Ito T; Mizuno T; Shinsako K; Hatano E; Uemoto S; Kamba T; Yamasaki T; Ogawa O; Seno H; Chiba T; Matsubara K
Clin Pharmacokinet; 2014 Feb; 53(2):185-96. PubMed ID: 24135988
[TBL] [Abstract][Full Text] [Related]
13. Transarterial administration of integrin inhibitor loaded nanoparticles combined with transarterial chemoembolization for treating hepatocellular carcinoma in a rat model.
Qian J; Oppermann E; Tran A; Imlau U; Qian K; Vogl TJ
World J Gastroenterol; 2016 Jun; 22(21):5042-9. PubMed ID: 27275096
[TBL] [Abstract][Full Text] [Related]
14. No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects.
Huang F; Ajavon A; Huang E; Lettieri J; Liu R; Peña C; Berse M
Thyroid; 2017 Sep; 27(9):1118-1127. PubMed ID: 28741453
[TBL] [Abstract][Full Text] [Related]
15. The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma.
Cho JY; Paik YH; Park HC; Yu JI; Sohn W; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2014 May; 34(5):795-801. PubMed ID: 24350564
[TBL] [Abstract][Full Text] [Related]
16. Chemoembolization with Vascular Disrupting Agent CKD-516 Dissolved in Ethiodized Oil in Combination with Doxorubicin: A VX2 Tumor Model Study.
Lee IJ; Lee M; Kim SJ; Kim YK; Won JY; Chung JW
J Vasc Interv Radiol; 2018 Aug; 29(8):1078-1084. PubMed ID: 29910164
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study.
Hsiao WD; Peng CY; Chuang PH; Lai HC; Cheng KS; Chou JW; Chen YY; Yu CJ; Feng CL; Su WP; Chen SH; Kao JT
BMC Gastroenterol; 2016 Apr; 16():50. PubMed ID: 27117280
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Chen L; Su H; Shao H; Xu K; Liang S; Liu J
Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
[TBL] [Abstract][Full Text] [Related]
19. Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2).
Kudo M; Arizumi T
Oncology; 2017; 93 Suppl 1():127-134. PubMed ID: 29258086
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.
Kim A; Widemann BC; Krailo M; Jayaprakash N; Fox E; Weigel B; Blaney SM
Pediatr Blood Cancer; 2015 Sep; 62(9):1562-6. PubMed ID: 26207356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
